An observational study in Non Small Cell Lung Cancer, sponsored by Guangdong Association of Clinical Trials. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-01.
Sponsored by Guangdong Association of Clinical Trials · Observational
This is an epidemiological,multicenter study of genomic and expression profiles of patients with newly diagnosed NSCLC.Two hundred and fifty NSCLC patients who fulfill the criteria are to be recruited by investigational sites.Approximately 100 of them will be from retrospectively collected samples with detailed clinical and 2-year follow-up information after surgeries.The demographics,cancer/adjacent normal tissue and matched blood sample will be collected after the patient had provided informed consent.All tissue samples will be analyzed for somatic mutations by exome deep sequencing,mRNA expression profiling by RNA sequencing and chromosome copy number variation by SNP array at the designated laboratories.
The 2-year follow-up information of all enrolled patients will be collected every 6 months.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 250 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Guangdong Association of Clinical Trials is the lead sponsor of 53 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study aims to collect approximately 250 smoking induced lung cancer(NSCLC) samples.Approximately 200 cases of treatment naive samples will be required. Samples will be collected mainly from the investigational sites in Guangzhou, Shanghai and Beijing that have expertise in lung cancer diagnosis.
Exclusion Criteria:
whole genome copy number variation in NSCLC patients
To indentify and characterize somatic mutations in coding region (exome) in NSCLC patients through next generation sequencing of the tumor and blood samples.To identify and characterize whole genome copy number variation in NSCLC patients by using the standard SNP array(Affymetrix SNP 6.0).To indentify and characterize the transcriptome of tumor versus adjacent normal tissues by using RNA sequencing.
Time frame: 2 years
Establish more effective therapy for lung cancer treatment in the future
To identify the changes in molecular pathways and biomarker related to smoking induced lung cancer to help establish more effective therapy for lung cancer treatment in the future.
Time frame: 2 years
No study locations are listed for this record.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangdong Association of Clinical Trials